Cellular Biotechnology Lab

Cellular Biotechnology Lab at ISCIII

Pediatric Cancer / Advanced Therapy / Immunotherapy

[Cellular Biotechnology Lab @LAB_BIOC]

Join us at ISCIII !!!

Focis on Advanced Therapies in pediatric cancer.

[Cellular Biotechnology Lab @LAB_BIOC]

oc

At ESGCT 2025, @Fesisisimo presented our results from a clinical trial of ALOCELYVIR in children with brain tumors, in a strong collaboration with Dr Álvaro Lassaletta and his team at Hospital Niño Jesús.

@APUpablougarte @AFANION_
@SaludISCIII

[Cellular Biotechnology Lab @LAB_BIOC]

We are looking for a postdoctoral researcher with solid expertise in tumor immunology to join our group BIOC (ISCIII), dedicated to immuotherapies on pediatric cancer research.

This opportunity is linked to the AECC postdoctoral fellowships.

Feel free to contact us !!

[Cellular Biotechnology Lab @LAB_BIOC]

@APUpablougarte @AFANION_

[Cellular Biotechnology Lab @LAB_BIOC]

Our group is presenting our latest results at the CICON25 Congress in Utrecht, a meeting with a special focus on immunotherapy of cancer

@SaludISCIII

[Cellular Biotechnology Lab @LAB_BIOC]

Un agradecimiento especial a las asociaciones de pacientes, @APUpablougarte y @AFANION_ , por si continuo apoyo a nuestro grupo y la investigación en nuevos tratamientos para el cáncer infantil

[Cellular Biotechnology Lab @LAB_BIOC]

@antonioper_mar

[Instituto de Salud Carlos III (ISCIII) @SaludISCIII]

Hoy arranca la jornada principal del Encuentro Internacional sobre Terapias Avanzadas, que celebramos en nuestro campus de Majadahonda. @red_terav
Más de 1️⃣0️⃣0️⃣ expertos se reúnen para compartir avances en terapias y salas blancas al servicio de los pacientes.

[Eva Bermejo-Sánchez, PhD @EvaBS14]

El Instituto de Salud Carlos III (ISCIII) acoge un encuentro internacional sobre terapias avanzadas. Organizado por el #IIER, con el apoyo de la Red Española de terapias Avanzadas (Red TERAV+ ISCIII).

https://t.co/GGZsGkjiRY

@JavierGC280 @l_marinas

[Cellular Biotechnology Lab @LAB_BIOC]

Join us May 28 at ISCIII Majadahonda (Madrid, Spain) 🏨for the Workshop on Adoptive Cell Therapies — dive into the latest on CAR-T and adoptive therapies 💉🧬

Free registration via email: [email protected]

Don't miss out!"

[SETGyC @SETGyC]

El 28 de mayo se celebra el 🔬 Workshop on Adoptive Cell Therapies en el Campus de Majadahonda del @SaludISCIII para compartir las últimas novedades en terapias celulares adoptivas y CAR-T 💉

📧 ¡Y es totalmente gratuito! Regístrate vía email a [email protected]

[Javier García Castro @JavierGC280]

🔬 Workshop on Adoptive Cell Therapies! 🔬

Open scientific workshop on May 28, 2025, hosted at the Majadahonda Campus of ISCIII (Madrid-Spain).

🎟️ Free access — but registration is required via email: [email protected]

[Cellular Biotechnology Lab @LAB_BIOC]

Coming soon, see you in Madrid (Majadahonda) !!!

[Javier García Castro @JavierGC280]

🧬 3rd INTERNATIONAL WORKSHOP on ADVANCED THERAPIES– register!
https://t.co/NUvW03rkhX

🏬 We are pleased to host this event at ISCIII, on our Majadahonda campus @SaludISCIII

💡 Cutting-edge science. A must-attend event for professionals in cell & gene therapy manufacturing

[Cellular Biotechnology Lab @LAB_BIOC]

In the pilot phase, no clinical responses were observed
in 18 patients unselected TILs.

However, when TILs were selected for neoantigen recognition, 3 responses were seen in 39 patients (7.7%).

Pembrolizumab
was added, and 8 objective responses were
seen in 34 patients (23.5%)

[Cellular Biotechnology Lab @LAB_BIOC]

Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies.

Minireview:
https://t.co/pdK3hvfcWb

[Cellular Biotechnology Lab @LAB_BIOC]

Now, AstraZeneca has announced plans to acquire EsoBiotec for up to 925 M€. The deal includes an initial payment of 389 M€, with up to 526 M€ contingent on achieving specific development and regulatory milestones.

https://t.co/fbZgW5M2VJ

[Cellular Biotechnology Lab @LAB_BIOC]

EsoBiotec SA has launched a clinical trial for ESO-T01, in vivo BCMA CAR-T therapy for multiple myeloma

ESO-T01 reprograms T cells directly using the ENaBL platform, which uses a viral vector said to be “immune shielded” via the removal of MHC1 and the overexpression of CD47

[Cellular Biotechnology Lab @LAB_BIOC]

The first patient received a single intravenous dose without prior lymphodepletion. After 28 days, their bone marrow showed no detectable cancer, and free light chain levels normalized, with no major side effects reported.

[Cellular Biotechnology Lab @LAB_BIOC]

T cell receptor precision editing of regulatory T cells for
celiac disease.

Authors generated gluten- reactive HLA- DQ2.5–restricted CD4+ engineered eTregs.

e Tregs hold therapeutic potential for restoring gluten
tolerance in their mice model.

https://t.co/RXyva1zMZW

[Amaya Mendikoetxea UAM @_amayamendiko]

La inversión en ciencia es rentable. Barcelona: un ejemplo a seguir 👇

[Javier García Castro @JavierGC280]

Hace 20 años que creamos nuestra Fundación. Hoy nos unimos a la UAM para seguir apoyando la investigación, los tratamientos y la formación en Oncología Pediátrica
Siempre agradecido de como me acogieron en el HNJS y los excelentes médicos que conocí y con los que sigo colaborando